{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:22:02Z","timestamp":1777904522437,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Plus"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.athplu.2025.07.002","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T22:50:59Z","timestamp":1752619859000},"page":"29-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Lp(a) in daily clinical routine: risk-factor for both cardiovascular events and heart-failure? A retrospective analysis of the Luebeck Lp(a) heart-failure (HF) registry in patients after myocardial infarction"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9895-590X","authenticated-orcid":false,"given":"Matthias","family":"Mezger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilmann","family":"Solle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Jurczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Fatum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicitas","family":"Lemmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Eitel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Paitazoglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"40","key":"10.1016\/j.athplu.2025.07.002_bib1","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1093\/eurheartj\/ehv428","article-title":"Cardiovascular disease in Europe \u2014 epidemiological update 2015","volume":"36","author":"Townsend","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2025.07.002_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117437","article-title":"Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: a cohort study from the UK biobank","volume":"389","author":"Welsh","year":"2024","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.athplu.2025.07.002_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and european atherosclerosis society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"39","key":"10.1016\/j.athplu.2025.07.002_bib4","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a european atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.athplu.2025.07.002_bib5","first-page":"269","article-title":"Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspectives","volume":"106","author":"Neumann","year":"2009","journal-title":"Dtsch Arztebl Int"},{"issue":"8","key":"10.1016\/j.athplu.2025.07.002_bib6","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"13","key":"10.1016\/j.athplu.2025.07.002_bib7","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.116.025941","article-title":"Age-specific trends in incidence, mortality, and comorbidities of heart failure in Denmark, 1995 to 2012","volume":"135","author":"Christiansen","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.athplu.2025.07.002_bib8","first-page":"236","article-title":"Heart failure","volume":"3","author":"Teng","year":"2010","journal-title":"Circulation: Heart Fail"},{"issue":"10155","key":"10.1016\/j.athplu.2025.07.002_bib9","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.athplu.2025.07.002_bib10","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017470","article-title":"Lipoprotein(a) and coronary artery disease risk without a family history of heart disease","volume":"10","author":"Finneran","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.athplu.2025.07.002_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","article-title":"Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective","volume":"349","author":"Arsenault","year":"2022","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.athplu.2025.07.002_bib12","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1161\/ATVBAHA.118.311220","article-title":"Lp(a) [Lipoprotein(a)]-Related risk of heart failure is evident in whites but not in other racial\/ethnic groups","volume":"38","author":"Steffen","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.athplu.2025.07.002_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102439","article-title":"Association between lipoprotein (a) and risk of heart failure: a systematic review and meta-analysis of Mendelian randomization studies","volume":"49","author":"Singh","year":"2024","journal-title":"Curr Probl Cardiol"},{"issue":"3","key":"10.1016\/j.athplu.2025.07.002_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0022-2275(20)41683-9","article-title":"Radioimmunoassay of human plasma Lp(a) lipoprotein","volume":"18","author":"Albers","year":"1977","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2025.07.002_bib15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on Lipoprotein(a): a call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.athplu.2025.07.002_bib16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000472175","article-title":"Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in caucasian, Asian, and African populations: the distribution of null alleles is non-random","volume":"4","author":"Kraft","year":"1996","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"10.1016\/j.athplu.2025.07.002_bib17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11883-024-01187-6","article-title":"Lipoprotein(a): from causality to treatment","volume":"26","author":"Kronenberg","year":"2024","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"10.1016\/j.athplu.2025.07.002_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/00045632231210682","article-title":"The current status of lipoprotein (a) measurement in clinical biochemistry laboratories in the UK: results of a 2021 national survey","volume":"61","author":"Ansari","year":"2023","journal-title":"Ann Clin Biochem"},{"issue":"7","key":"10.1016\/j.athplu.2025.07.002_bib19","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/eurjpc\/zwae032","article-title":"Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research","volume":"31","author":"Kamstrup","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.athplu.2025.07.002_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.atherosclerosis.2023.01.014","article-title":"Trends and consequences of lipoprotein(a) testing: cross-Sectional and longitudinal health insurance claims database analyses","volume":"367","author":"St\u00fcrzebecher","year":"2023","journal-title":"Atherosclerosis"},{"issue":"23","key":"10.1016\/j.athplu.2025.07.002_bib21","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.athplu.2025.07.002_bib22","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ahj.2004.08.027","article-title":"Ethnic differences in cardiovascular risk factor burden among middle-aged women: study of Women's health across the nation (SWAN)","volume":"149","author":"Matthews","year":"2005","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.athplu.2025.07.002_bib23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11789-017-0087-y","article-title":"Incidence of elevated lipoprotein (a) levels in a large cohort of patients with cardiovascular disease","volume":"12","author":"van Buuren","year":"2017","journal-title":"Clin Res Cardiol Suppl"},{"key":"10.1016\/j.athplu.2025.07.002_bib24","article-title":"Prevalence of elevated lipoprotein(a) in cardiac rehabilitation patients \u2014 results from a large-scale multicentre registry in Germany","author":"Altmann","year":"2024","journal-title":"Clin Res Cardiol"},{"issue":"37","key":"10.1016\/j.athplu.2025.07.002_bib25","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"36","key":"10.1016\/j.athplu.2025.07.002_bib26","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.athplu.2025.07.002_bib27","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ejhf.822","article-title":"Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland","volume":"19","author":"Mamas","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.athplu.2025.07.002_bib28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.atherosclerosis.2017.05.014","article-title":"The association of lipoprotein(a) with incident heart failure hospitalization: atherosclerosis risk in communities study","volume":"262","author":"Agarwala","year":"2017","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.athplu.2025.07.002_bib29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jchf.2015.08.006","article-title":"Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population","volume":"4","author":"Kamstrup","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10.1016\/j.athplu.2025.07.002_bib30","first-page":"197","article-title":"High level of lipoprotein(a) as predictor for recurrent heart failure in patients with chronic heart failure: a cohort study","volume":"113","author":"Yan","year":"2019","journal-title":"Arq Bras Cardiol"},{"issue":"16","key":"10.1016\/j.athplu.2025.07.002_bib31","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jacc.2023.02.033","article-title":"Clinical trial design for lipoprotein(a)-lowering therapies: JACC focus seminar 2\/3","volume":"81","author":"Malick","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"9493","key":"10.1016\/j.athplu.2025.07.002_bib32","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"10057","key":"10.1016\/j.athplu.2025.07.002_bib33","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.athplu.2025.07.002_bib34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"}],"container-title":["Atherosclerosis Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089525000185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089525000185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:27:09Z","timestamp":1777638429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667089525000185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":34,"alternative-id":["S2667089525000185"],"URL":"https:\/\/doi.org\/10.1016\/j.athplu.2025.07.002","relation":{},"ISSN":["2667-0895"],"issn-type":[{"value":"2667-0895","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lp(a) in daily clinical routine: risk-factor for both cardiovascular events and heart-failure? A retrospective analysis of the Luebeck Lp(a) heart-failure (HF) registry in patients after myocardial infarction","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Plus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athplu.2025.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}